Patents by Inventor Yue-Mei Zhang

Yue-Mei Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
    Publication number: 20180117170
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: October 26, 2017
    Publication date: May 3, 2018
    Inventors: Mark Macielag, Raymond J Patch, Rui Zhang, Martin A Case, Shamina M Rangwala, James N Leonard, Raul C Camacho, Michael J Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V Swanson, Wenying Jian, Yue-Mei Zhang, Mark Wall, Ellen Chi
  • SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20170362196
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Application
    Filed: September 7, 2017
    Publication date: December 21, 2017
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
    Patent number: 9815790
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: November 14, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Barry A. Springer, William V. Murray
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 9790198
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 17, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Cinnoline derivatives useful as CB-1 receptor inverse agonists
    Patent number: 9732061
    Abstract: The present invention is directed to cinnoline derivatives pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: August 15, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Joseph Macielag, Yue-Mei Zhang, Bart L. DeCorte, Michael N. Greco, Donald W. Ludovici, Michael H. Parker
  • Quinazoline derivatives useful as CB-1 inverse agonists
    Patent number: 9682955
    Abstract: The present invention is directed to quinazoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 20, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Joseph Macielag, Yue-Mei Zhang, Bart L. DeCorte, Michael N. Greco
  • BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20170057929
    Abstract: The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: August 23, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Rui Zhang, Yue-Mei Zhang, Bin Zhu, Michael H. Parker, Donald W. Ludovici, Daniel J. Parks, Bart L. DeCorte, Michael N. Greco
  • CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20170057922
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.
    Type: Application
    Filed: August 17, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Barry A. Springer, William V. Murray
  • Quinoline derivatives useful as CB-1 inverse agonists
    Patent number: 9464055
    Abstract: The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: October 11, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Mark Macielag, Michael Greco, Yue-Mei Zhang, Christopher Teleha
  • CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS
    Publication number: 20160200719
    Abstract: The present invention is directed to cinnoline derivatives pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 14, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark Joseph Macielag, Yue-Mei Zhang, Bart L. DeCorte, Michael N. Greco, Donald W. Ludovici, Michael H. Parker
  • SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
    Publication number: 20160102071
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Application
    Filed: October 8, 2015
    Publication date: April 14, 2016
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Quinazoline Derivatives Useful as CB-1 Inverse Agonists
    Publication number: 20160068512
    Abstract: The present invention is directed to quinazoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: September 3, 2015
    Publication date: March 10, 2016
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Mark Joseph Macielag, Yue-Mei Zhang, Bart L. DeCorte, Michael N. Greco
  • Quinoline derivatives useful as CB-1 inverse agonists
    Patent number: 9266835
    Abstract: The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: February 23, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Bart DeCorte, Mark Macielag, Michael Greco, Yue-Mei Zhang, Christopher Teleha
  • QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20150239845
    Abstract: The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: February 6, 2015
    Publication date: August 27, 2015
    Inventors: Bart DeCORTE, Mark Macielag, Michael Greco, Yue-Mei Zhang, Christopher Teleha
  • QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20150239844
    Abstract: The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    Type: Application
    Filed: February 6, 2015
    Publication date: August 27, 2015
    Inventors: Bart DeCORTE, Mark MACIELAG, Michael GRECO, Yue-Mei ZHANG, Christopher TELEHA
  • Azetidinyl diamides as monoacylglycerol lipase inhibitors
    Patent number: 8962607
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Y, Z, R1, and s are defined herein.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: February 24, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Haiyan Bian, Kristen Chevalier, Jose Clemente, Peter J Connolly, Christopher Flores, Shu-Chen Lin, Li Liu, John Mabus, Mark Macielag, Mark M McDonnell, Philip M Pitis, Yue-Mei Zhang, Sui-Po Zhang, Bin Zhu
  • Phenoxy-substituted pyrimidines as opioid receptor modulators
    Patent number: 8895573
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R1, Y, R2, R3, and Ra are defined herein.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: November 25, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Steven J Coats, Yue-Mei Zhang, Shu-Chen Lin, Li Liu, Tamara A Miskowski, Scott L. Dax, Henry J Breslin, Bart L. De Corte, Wei He
  • AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
    Publication number: 20140243305
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Y, Z, R1, and s are defined herein.
    Type: Application
    Filed: April 22, 2013
    Publication date: August 28, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Haiyan Bian, Kristen Chevalier, Jose Clemente, Peter J. Connolly, Christopher Flores, Shu-Chen Lin, Li Liu, John Mabus, Mark Macielag, Mark M. McDonnell, Philip M. Pitis, Yue-Mei Zhang, Sui-Po Zhang, Bin Zhu
  • Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
    Patent number: 8748417
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: wherein Y, Z, and R1, and R2 are defined herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 10, 2014
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Yue-Mei Zhang, Peter J. Connolly, Shu-Chen Lin, Mark J. Macielag
  • Azetidinyl diamides as monoacylglycerol lipase inhibitors
    Patent number: 8741887
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Y, Z, R1, and s are defined herein.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: June 3, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Haiyan Bian, Kristen Chevalier, Jose Clemente, Pete Connolly, Chris Flores, Shu-Chen Lin, Li Liu, John Mabus, Mark Macielag, Mark McDonnell, Philip Pitis, Yue-Mei Zhang, Sui-Po Zhang, Bin Zhu